MLYS Earnings Prediction
The chart below shows how MLYS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MLYS sees a -1.25% change in stock price 10 days leading up to the earnings, and a -9.30% change 10 days following the report. On the earnings day itself, the stock moves by +1.68%. This data can give you a slight idea of what to expect for the next quarter's release.
MLYS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.98
-60.66%
-13.27%
No Data Available
MLYS Earnings Analysis
Mineralys Therapeutics Inc Corporation (MLYS.O) Earnings Conference Call
Positive
Clinical Trial Progress: The ADVANCE HTN trial enrolled 285 subjects, with top line data expected in March 2025, indicating strong progress in clinical trials for uncontrolled hypertension.
Lorondristat Efficacy Trial: The LAUNCH HTN trial has enrolled 1,083 subjects, designed to confirm the efficacy of lorondristat, with anticipated top line data in the mid-first half of 2025, showcasing robust patient engagement.
Strong Financial Position: The company ended Q4 2024 with cash, cash equivalents, and investments totaling $198.2 million, sufficient to fund clinical studies through Q1 2026, reflecting strong financial health.
Other Income Growth: The total other income net for the year ended 12/31/2024 was $14.6 million, an increase from $12.8 million in 2023, indicating improved financial performance from investments.
Clinical Trial Enrollment Complete: The company has completed enrollment in the EXPLORER CKD Phase II trial, which is expected to provide valuable data on the efficacy of lorondristat in treating hypertension in chronic kidney disease patients, with top line data anticipated in Q2 2025.
Negative
Significant Net Loss Increase: Net loss increased significantly to $177.8 million for the year ended 12/31/2024, compared to $71.9 million for the year ended 12/31/2023, indicating a worsening financial position.
R&D Expense Surge: R&D expenses surged to $168.6 million for the year ended 12/31/2024, up from $70.4 million in the previous year, reflecting escalating costs without corresponding revenue growth.
Rising G&A Expenses: G&A expenses rose to $23.8 million for the year ended 12/31/2024, compared to $14.3 million for the year ended 12/31/2023, highlighting increased operational costs amid financial losses.
Liquidity Concerns: Cash, cash equivalents, and investments decreased to $198.2 million as of 12/31/2024, down from $239 million a year earlier, raising concerns about liquidity for future operations.
Decline in Other Income: Total other income net for the quarter ended 12/31/2024 fell to $2.8 million, down from $3.3 million for the same quarter in 2023, indicating declining income streams.
MLYS FAQs
How does MLYS typically perform around its earnings report dates?
Is Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MLYS Earning Call Sentiment
Earnings call transcript: Mineralys Therapeutics Q4 2024 misses EPS forecast
MLYS.O
2.89%Positive
The earnings call reveals increased R&D and G&A expenses, leading to a widened net loss, which is a concern. Despite positive trial enrollments and a strong cash position, management's vague responses in the Q&A, particularly on timelines and compliance, add uncertainty. No new partnerships or shareholder returns were mentioned. The financial performance and lack of clear guidance suggest a negative stock reaction.
